Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

The use of point‐of‐care testing in detecting platelet function recovery in a patient treated with prasugrel undergoing urgent surgical revascularization (CROSBI ID 304091)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Verzelloni Sef, Alessandra ; Caliandro, Francesca ; Sef, Davorin ; Raja, Shahzad G. The use of point‐of‐care testing in detecting platelet function recovery in a patient treated with prasugrel undergoing urgent surgical revascularization // Journal of cardiac surgery, 36 (2021), 12; 4801-4804. doi: 10.1111/jocs.16035

Podaci o odgovornosti

Verzelloni Sef, Alessandra ; Caliandro, Francesca ; Sef, Davorin ; Raja, Shahzad G.

engleski

The use of point‐of‐care testing in detecting platelet function recovery in a patient treated with prasugrel undergoing urgent surgical revascularization

A recent administration of potent P2Y12 receptor inhibitor such as prasugrel in patients undergoing cardiac surgery remains a dilemma and little is known about its impact on platelet function recovery. Guidelines recommend discontinuation of prasugrel 7 days before surgery to reduce the risk of surgery-related bleeding. Patients at risk may benefit from preoperative platelet function testing to guide individualized preoperative waiting time. We present a rare case of complete function recovery in a patient treated with prasugrel revealed by preoperative platelet function monitoring before urgent coronary artery bypass surgery (CABG). A complete platelet function recovery was revealed by platelet function testing after discontinuation of prasugrel for four days and patient underwent urgent CABG without increased risk of postoperative bleeding. Our case with a review of literature emphasized that the decision to proceed with urgent CABG in a patient recently treated with prasugrel should be based on a personalized risk assessment and might be supported by preoperative platelet function monitoring to shorten the waiting time.

antiplatelet therapy ; coronary artery bypass grafting ; point-of-care ; prasugrel.

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

36 (12)

2021.

4801-4804

objavljeno

0886-0440

1540-8191

10.1111/jocs.16035

Povezanost rada

Povezane osobe



Kliničke medicinske znanosti

Poveznice
Indeksiranost